Centerline Biomedical
Revolutionizing Interventional Procedures with IOPS Technology

Amidst the evolving landscape of healthcare and the increasing number of CVD cases across the globe, the vascular procedures market has witnessed substantial growth, reaching a valuation of $2.5 billion in 2022, with projections soaring to $4.14 billion by 2030. Similarly, the interventional market saw a robust start in 2021, with a revenue of $3,929.2 million, poised to ascend further at a steady 3.8 percent CAGR till 2030, foreseeing a total value of $5,501.7 million.

Currently, physicians use 2-dimensional X-ray fluoroscopy to navigate through complex anatomies. However, this technology has several additional limitations, such as the inability to visualize soft tissue and the risk of exposure to harmful ionizing radiation.

Centerline Biomedical, a leader in surgical navigation innovation, equips physicians with real-time imaging and sensorized medical device solutions to improve outcomes, lower costs, and reduce radiation exposure in minimally invasive endovascular procedures. Founded in 2014 as a spinoff from the Cleveland Clinic, the company commercializes novel vascular navigation technology rooted in the Clinic’s renowned Lerner Research Institute’s Heart and Vascular Institute.

Committed to changing the way doctors visualize when performing life-saving therapies, the Centerline Biomedical multidisciplinary team of scientists, clinicians, engineers, and software architects has developed its flagship product, the Intra-Operative Positioning System (IOPS^®). The IOPS device, housed on a cart, seamlessly integrates into hybrid operating rooms. This mobile and affordable 3D vascular navigation system offers greater visualization for positioning accuracy, simplifying complex procedures and potentially decreasing complications, such as endoleaks or costly secondary interventions.

Designed to enhance image guidance for transcatheter interventions, IOPS provides a vivid, intuitive three-dimensional view. When paired with IOPS-specialized endovascular devices, the system empowers physicians to navigate procedures with unparalleled precision. Its electromagnetic tracking system, comparable to a GPS used for tracking location and direction, enables real-time views and directional guidance of its sensorized guidewires and catheters.

The result is a comprehensive and detailed visualization of the patient's vasculature for navigation with endovascular devices that elevates the accuracy and efficiency of minimally invasive procedures.

“IOPS creates manipulable 3D maps of the relevant anatomy. It also provides real-time 3D image guidance for the devices in those maps without the constant radiation exposure that’s part of today’s standard practice. It does this while fitting into existing workflows and using images that are already part of the standard of care,” says Vikash Goel, founder and CTO of Centerline Biomedical.

Centerline Biomedical's journey is not just about present accomplishments but also about future possibilities. The underlying IOPS platform has reached far beyond the aortic endovascular arena in which it is being used today. The company boasts a dynamic scientific advisory board comprising global thought leaders in various medical domains and research initiatives that apply the platform to areas such as structural heart, peripheral, and neurovascular interventions. The technology also has applications in predictive modeling, clinical decision support, healthcare analytics, and the education and training of future surgeons and interventionalists.

IOPS creates manipulable 3D maps of the relevant anatomy. And it provides real-time 3D image guidance of the devices in those maps, without the constant radiation exposure that’s part of today’s standard practice. It does this while fitting into existing workflows and using images that are already part of the standard of care.

What sets Centerline Biomedical apart is the technological prowess embedded in IOPS and the holistic impact it brings to patient care. Beyond improving patient outcomes and procedure costs, the company aims to minimize reliance on X-ray fluoroscopy, mitigating radiation exposure times and risks. This multi-pronged approach to providing healthcare solutions underscores Centerline Biomedical's commitment to advancing healthcare while prioritizing the well-being of patients and medical professionals.

Centerline Biomedical emerges as a trailblazer in the healthcare landscape. By addressing an unmet clinical need, developing cutting-edge technology, and maintaining a forward-thinking approach, the company stands at the forefront of innovation. The stories of individuals treated by IOPS exemplify a paradigm shift in healthcare—one that honors the past, enhances the present, and envisions a future where long-term care of both patient and provider health takes center stage.